135 related articles for article (PubMed ID: 23597048)
21. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
22. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
Dowell JE; Minna JD
Nat Clin Pract Oncol; 2004 Nov; 1(1):2-3. PubMed ID: 16264773
[No Abstract] [Full Text] [Related]
23. EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report.
Huang MJ; Lim KH; Tzen CY; Hsu HS; Yen Y; Huang BS
Lung Cancer; 2005 Sep; 49(3):413-5. PubMed ID: 15913841
[TBL] [Abstract][Full Text] [Related]
24. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
25. Perspectives in Lung Cancer--Third Asian-pacific Conference. 11-12 September 2009, Bangkok, Thailand.
Lopes Gde L
IDrugs; 2009 Nov; 12(11):689-91. PubMed ID: 19844853
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor mutations in lung cancer.
Sharma SV; Bell DW; Settleman J; Haber DA
Nat Rev Cancer; 2007 Mar; 7(3):169-81. PubMed ID: 17318210
[TBL] [Abstract][Full Text] [Related]
27. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.
Remon J; Morán T; Majem M; Reguart N; Dalmau E; Márquez-Medina D; Lianes P
Cancer Treat Rev; 2014 Feb; 40(1):93-101. PubMed ID: 23829935
[TBL] [Abstract][Full Text] [Related]
28. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer.
Yoshida T; Zhang G; Haura EB
Biochem Pharmacol; 2010 Sep; 80(5):613-23. PubMed ID: 20519133
[TBL] [Abstract][Full Text] [Related]
29. Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.
Santarpia M; Altavilla G; Salazar MF; Magri I; Pettineo G; Benecchi S; Rosell R
Expert Rev Respir Med; 2011 Jun; 5(3):413-24. PubMed ID: 21702662
[TBL] [Abstract][Full Text] [Related]
30. First-line therapy of mutated non-small cell lung cancer: an update.
Stöhlmacher-Williams J
Onkologie; 2012; 35(5):293-9. PubMed ID: 22868512
[TBL] [Abstract][Full Text] [Related]
31. Targeted therapy for non-small cell lung cancer.
Toloza EM; D'Amico TA
Semin Thorac Cardiovasc Surg; 2005; 17(3):199-204. PubMed ID: 16253823
[TBL] [Abstract][Full Text] [Related]
32. Biomarker testing in non-small cell lung cancer: a clinician's perspective.
Bernicker E
Arch Pathol Lab Med; 2015 Apr; 139(4):448-50. PubMed ID: 25166873
[No Abstract] [Full Text] [Related]
33. [Research progress of targeted therapy in non-small cell lung cancer brain metastases].
Jiang T; Zhou C
Zhongguo Fei Ai Za Zhi; 2014 Nov; 17(11):824-8. PubMed ID: 25404274
[TBL] [Abstract][Full Text] [Related]
34. Personalized therapy for lung cancer.
Moreira AL; Eng J
Chest; 2014 Dec; 146(6):1649-1657. PubMed ID: 25451351
[TBL] [Abstract][Full Text] [Related]
35. How Targeted Therapies Are Changing Treatment for Non-Small Cell Lung Cancer.
Becze E
ONS Connect; 2016 Feb; 31(2):24-5. PubMed ID: 26930998
[No Abstract] [Full Text] [Related]
36. Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.
Albaba H; Lim C; Leighl NB
Pharmacoeconomics; 2017 Dec; 35(12):1195-1209. PubMed ID: 28861770
[TBL] [Abstract][Full Text] [Related]
37. Molecular targeted therapy in lung cancer.
Fujioka N; Bitterman PB
Minn Med; 2012 Oct; 95(10):38-41. PubMed ID: 23193704
[TBL] [Abstract][Full Text] [Related]
38. [Not Available].
Evers G; Mohr M; Kerkhoff A; Lenz G; Wiewrodt R; Schmidt LH
Dtsch Med Wochenschr; 2017 Oct; 142(20):1531-1534. PubMed ID: 29017211
[TBL] [Abstract][Full Text] [Related]
39. Lung cancer. Dacomitinib: getting on target after negative ARCHER trial.
Hutchinson L
Nat Rev Clin Oncol; 2015 Jan; 12(1):3. PubMed ID: 25421284
[No Abstract] [Full Text] [Related]
40. [Lung cancer: progress in diagnosis and treatments. Topics: III. Treatment; 3. Chemotherapy for patients with non-small cell lung cancer, 2) Driver mutation and molecular-targeted therapy in lung cancer].
Maemondo M
Nihon Naika Gakkai Zasshi; 2014 Jun; 103(6):1314-21. PubMed ID: 25151796
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
